The U.S. Court of Appeals for the Federal Circuit in Washington ruled that Mutual's version of the drug did not infringe AstraZeneca's patent.

But in a consolation prize for AstraZeneca, the appeals court upheld the patent, which expires in 2007. The ruling could give Astra ammunition in its legal battle to prevent Ivax Corp. from marketing its own generic version...